Role of MBD3-SOX2 axis in residual myeloma following pomalidomide

Saved in:
Bibliographic Details
Published inLeukemia Vol. 35; no. 11; pp. 3319 - 3323
Main Authors Verma, Rakesh, Branagan, Andrew R, Xu, Mina L, Flavell, Richard A, Dhodapkar, Kavita M, Dhodapkar, Madhav V
Format Journal Article
LanguageEnglish
Published England Nature Publishing Group 01.11.2021
Subjects
Angiogenesis Inhibitors - adverse effects
Biomarkers, Tumor - genetics
Biomarkers, Tumor - metabolism
Biopsy
Bone marrow
DNA-Binding Proteins - genetics
DNA-Binding Proteins - metabolism
Drug therapy
Gene expression
Gene Expression Regulation, Neoplastic - drug effects
Genetic aspects
Health aspects
Hematology
Humans
MBD3 protein
Multiple myeloma
Multiple Myeloma - drug therapy
Multiple Myeloma - pathology
Myeloma
Neoplasm Recurrence, Local - drug therapy
Neoplasm Recurrence, Local - pathology
Neoplasm, Residual - chemically induced
Neoplasm, Residual - genetics
Neoplasm, Residual - metabolism
Neoplasm, Residual - pathology
Patient outcomes
Prognosis
Proteins
SOXB1 Transcription Factors - genetics
SOXB1 Transcription Factors - metabolism
Stem cells
Thalidomide - adverse effects
Thalidomide - analogs & derivatives
Transcription factors
Tumor Cells, Cultured
Xenograft Model Antitumor Assays
United States
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
RV designed and performed experiments and wrote the manuscript. AB and KD performed clinical research and provided access to specimens. MLX provided help with immunohis-tochemical analyses. RAF provided access to mice used in the study. MVD provided oversight for the project and wrote manuscript. All authors contributed to interpretation of data and approved the final manuscript.
Author contributions
ISSN:0887-6924
1476-5551
DOI:10.1038/s41375-021-01145-0